Mumbai, March 6 -- According to an exchange filing, the alliance focuses on transferring the technology for Vorinostat, a key medication used to treat Cutaneous T-Cell Lymphoma (CTCL), a rare blood-originated skin cancer that is currently unavailable in India. This collaboration aims to revolutionize the treatment landscape for CTCL patients by providing access to domestically produced, high-quality Vorinostat.

In line with the Make in India initiative, the company plans to scale up production of Vorinostat and introduce it to the Indian market, leveraging NIPER Ahmedabad's expertise. The company also expressed its commitment to social responsibility, stating it would provide Vorinostat free of charge to economically disadvantaged patien...